News

Wisp partnered with Visby Medical to expand access to Visby’s at-home sexually transmitted infection test and provide follow-up treatment through Wisp’s telehealth platform. The post Wisp, Visby Partner to Expand Access to At-Home STI Test appeared first on MedCity News.

CMS is rolling out its health tech ecosystem initiative with a new Medicare app library that functions like a healthcare “App Store,” aiming to make patient data more portable and accessible across vetted digital health apps. The post CMS’ New ‘App Store’ Is Trying to Turn Interoperability Into a Digital Health Distribution System appeared first […]

The fatty liver disease MASH is one of the metabolic disorders that Nula Therapeutics is pursuing. The startup’s small molecules are intended to restore the integrity of the nuclear envelope, a cellular membrane whose dysfunction can contribute to metabolic disease. The post Startup Nula Emerges to Advance a New Class of Medicines for Metabolic Disease […]

Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care. The post The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease appeared first on MedCity News.

The difference between that last era and this one isn’t incremental. It’s categorical. Artificial intelligence isn’t optimizing the old system. It’s making the old system economically indefensible. The post The End of Incrementalism: Why Healthcare Innovation is Finally Reshaping the Model appeared first on MedCity News.

Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased. The post New Bill Seeks to Lower Out-of-Pocket Drug Costs appeared first on MedCity News.

Innovaccer is committing $250 million to expand its AI agent platform, which automates workflows across areas like prior authorization, revenue cycle management and population health. The move comes amid an ongoing debate over whether administrative AI tools can ultimately reduce costs for providers. The post Why Innovaccer Is Pouring $250M into Its Agentic AI Platform […]

Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors appeared first on […]

These products have yet to offer treatment solutions designed to get users from their current health state to a desired future health state. This creates a massive, untapped opening for tools that move people from awareness to action in a clinically meaningful way, without the cost and access barriers of engaging the healthcare system or requiring […]

The next wave of radiology AI value will come from closed-loop follow-up. An actionable finding should start a pathway with a measurable end state: the follow-up exam is completed, the referral is completed, or the recommendation is clinically resolved with a documented rationale. The post The Last Mile Problem in AI Radiology: Detection Improves, Follow-Through […]

HeartFlow, which makes AI tools to analyze cardiac images, sued its rival Cleerly, alleging infringement on six patents. Cleerly is pushing back. The post Heartflow Sues Cardiac AI Rival Cleerly Over Alleged IP Theft appeared first on MedCity News.

Vida Health is partnering with ŌURA to use data from the Oura Ring to provide more continuous, personalized cardiometabolic care and improve patient outcomes. The post Vida Health Teams Up with ŌURA to Provide More Personalized Metabolic Care appeared first on MedCity News.

Travere Therapeutics’ Filspari is now the first FDA-approved drug for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. Analysts project the pill will become a blockbuster seller. The post Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease appeared first on MedCity News.

[Sponsored] 74% of healthcare AI is stuck in pilots. The reason isn’t the AI, it’s the data architecture underneath it. Read more to find the solution. The post 5 of the Top 10 U.S. Health Systems Are Moving to This New Health IT Category. Here’s Why. appeared first on MedCity News.

To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis. The post Why Synthetic Data is the Antidote to Clinical Trials appeared first on MedCity News.

The question is where will healthcare see the greatest value? Here are five use cases that define the greatest ROI for leveraging agentic AI for clinical supply chain operations. The post Clinical Supply Chain Hits Its AI Turning Point appeared first on MedCity News.

Hospitals are still on quite fragile financial footing if you look beneath the surface, according to new Kaufman Hall data. Rising costs, uneven patient volumes, and ongoing reimbursement and payer mix pressures continue to limit the sector’s financial recovery. The post Hospital Margins Squeeze as Costs Outpace Revenue Growth appeared first on MedCity News.

New research from the Elevance Health Public Policy Institute finds that higher enrollment in Medicare Advantage may be linked to lower overall Medicare spending. The post Report: Growth in MA Is Associated With Lower Total Medicare Spending appeared first on MedCity News.

Revolutions Medicines’ daraxonrasib met the main goals of its Phase 3 test in pancreatic cancer, posting results that were both statistically significant and clinically meaningful. The company now plans to file for speedy regulatory approval under a new FDA pilot program. The post Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial appeared first […]

While many AI conversations revolve around regulated industry transformation, the question is where to actually start in a way that does not break trust, budgets or regulatory limits. The post The AI Value Gap and Why Validation is a Practical First Win for Life Sciences appeared first on MedCity News.